Fig. 3.

Administration of SPAK inhibitor ZT-1a at 2–4 weeks post-BCAS attenuates neurological behavioral deficits in mice. A Experimental protocol. C57BL/6 J mice underwent sham or BCAS surgery. BCAS mice received either vehicle (100% DMSO, 2 ml/kg body weight/ day) or ZT-1a (5 mg/kg body weigh/day) via intraperitoneal injection (i.p.) from 14 to 28 days. Arrowheads: indicate the time points at which drug treatment, behavior, IF, WB or flow cytometry were performed. B Illustration of animal total distance traveled in the Open field test. C Summary of travel distance and vertical movement counts. Data are represented as mean ± SD. n = 7–8 mice. *p < 0.05, **p < 0.01. One-way analysis of variance (ANOVA). D Y-maze spontaneous alternation test. The percentage of spontaneous alternation and total entry in Y maze test was shown. Data are mean ± SD, n = 6–8 mice. *p < 0.05. One-way analysis of variance (ANOVA)